AT445015T - Method for producing recombinant, lipid-modified psaa proteins and their use - Google Patents

Method for producing recombinant, lipid-modified psaa proteins and their use

Info

Publication number
AT445015T
AT445015T AT99903011T AT99903011T AT445015T AT 445015 T AT445015 T AT 445015T AT 99903011 T AT99903011 T AT 99903011T AT 99903011 T AT99903011 T AT 99903011T AT 445015 T AT445015 T AT 445015T
Authority
AT
Austria
Prior art keywords
lipid
modified
use
method
producing recombinant
Prior art date
Application number
AT99903011T
Other languages
German (de)
Inventor
Edwin Ades
George Carlone
Barun De
Jacquelyn Sampson
Robert Huebner
Original Assignee
Ct Disease Contr & Prevention
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US1778298A priority Critical
Application filed by Ct Disease Contr & Prevention filed Critical Ct Disease Contr & Prevention
Priority to PCT/US1999/000379 priority patent/WO1999040200A1/en
Publication of AT445015T publication Critical patent/AT445015T/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/38—Medical treatment of vector-borne diseases characterised by the agent
    • Y02A50/398—Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a bacteria
    • Y02A50/399—Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a bacteria of the genus Borrellia
    • Y02A50/401—Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a bacteria of the genus Borrellia the bacteria being Borrelia burgdorferi, i.e. Lyme disease or Lyme borreliosis
AT99903011T 1998-02-03 1999-01-14 Method for producing recombinant, lipid-modified psaa proteins and their use AT445015T (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US1778298A true 1998-02-03 1998-02-03
PCT/US1999/000379 WO1999040200A1 (en) 1998-02-03 1999-01-14 RECOMBINANT LIPIDATED PsaA PROTEIN, METHODS OF PREPARATION AND USE

Publications (1)

Publication Number Publication Date
AT445015T true AT445015T (en) 2009-10-15

Family

ID=21784518

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99903011T AT445015T (en) 1998-02-03 1999-01-14 Method for producing recombinant, lipid-modified psaa proteins and their use

Country Status (13)

Country Link
US (2) US7635486B1 (en)
EP (1) EP1053329B1 (en)
JP (1) JP4290875B2 (en)
AT (1) AT445015T (en)
AU (1) AU2313199A (en)
BR (1) BR9909097A (en)
CA (1) CA2319404C (en)
DE (1) DE69941505D1 (en)
DK (1) DK1053329T3 (en)
ES (1) ES2334185T3 (en)
NZ (1) NZ525674A (en)
PT (1) PT1053329E (en)
WO (1) WO1999040200A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903184B1 (en) 1998-03-02 2005-06-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Multiple antigenic peptides immunogenic against Streptococcus pneumonia
AU2001271935B2 (en) * 2000-07-10 2006-09-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Multiple antigenic peptides immunogenic against streptococcus pneumoniae
AU3948801A (en) * 2000-02-28 2001-09-12 Chiron Spa Heterologous expression of neisserial proteins
MX339524B (en) 2001-10-11 2016-05-30 Wyeth Corp Novel immunogenic compositions for the prevention and treatment of meningococcal disease.
CN1867354A (en) * 2003-04-16 2006-11-22 惠氏控股有限公司 Novel immunogenic compositions for the prevention and treatment of meningococcal disease
AR064642A1 (en) 2006-12-22 2009-04-15 Wyeth Corp Polynucleotide vector that comprises recombinant cell comprising the vector polypeptide, antibody, composition comprising the polynucleotide, vector, polypeptide or antibody recombinant cell, using the composition and method for preparing the same composition and prepare a composi
KR101594228B1 (en) 2010-08-23 2016-02-15 와이어쓰 엘엘씨 STABLE FORMULATIONS OF NEISSERIA MENINGITIDIS rLP2086 ANTIGENS
ES2585328T3 (en) 2010-09-10 2016-10-05 Wyeth Llc Non-lipidated variants of ORF2086 antigens from Neisseria meningitidis
US10196429B2 (en) 2012-03-09 2019-02-05 Pfizer Inc. Neisseria meningitidis composition and methods thereof
PE20190458A1 (en) 2012-03-09 2019-04-01 Pfizer Neisseria meningitidis compositions and methods thereof
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (en) 2013-09-08 2018-07-31 Пфайзер Инк. Immunogenic composition for neisseria meningitidis (options)
CN103773779B (en) * 2013-12-31 2017-02-15 李越希 Gene segment of chemosynthetic streptococcus pneumoniae surface adhesin A as well as expression and application of gene segment
WO2017096486A1 (en) 2015-12-10 2017-06-15 National Research Council Of Canada Lipidated streptococcus pneumoniae antigen compositions, methods of preparation and use
KR20190112081A (en) 2017-01-31 2019-10-02 화이자 인코포레이티드 Neisseria meningitidis composition and method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3065892A (en) * 1991-11-14 1993-06-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Pneumococcal fimbrial protein a vaccines
DE69636544T2 (en) * 1995-06-07 2007-06-06 Sanofi Pasteur, Inc. Expression of lipoproteins
US6924112B1 (en) * 1997-12-04 2005-08-02 Biomethodes S.A.R.L. Cloning method by multiple-digestion, vectors for implementing same and applications
NO983911D0 (en) * 1998-08-26 1998-08-26 Norsk Hydro As Alginate capsules for use in the treatment of brain tumor

Also Published As

Publication number Publication date
EP1053329A1 (en) 2000-11-22
JP2002505083A (en) 2002-02-19
JP4290875B2 (en) 2009-07-08
ES2334185T3 (en) 2010-03-05
US7960535B2 (en) 2011-06-14
CA2319404A1 (en) 1999-08-12
DE69941505D1 (en) 2009-11-19
PT1053329E (en) 2010-01-04
AU2313199A (en) 1999-08-23
EP1053329B1 (en) 2009-10-07
DK1053329T3 (en) 2010-01-25
CA2319404C (en) 2014-01-07
NZ525674A (en) 2005-01-28
BR9909097A (en) 2000-12-05
WO1999040200A1 (en) 1999-08-12
US7635486B1 (en) 2009-12-22
US20100260802A1 (en) 2010-10-14

Similar Documents

Publication Publication Date Title
DE69838062D1 (en) Human monoclonal antibodies against the epidermal growth factor receptor
DE69936050D1 (en) Graben-gate semiconductor components and method for the production thereof
DE69733146D1 (en) Recombinant toxin fragments
DK0954588T3 (en) OB fusion protein compositions and methods
DE69939070D1 (en) Method for quantitating human waxes
DE69834401D1 (en) Businterfacesystem and method
DE69930254D1 (en) Microstructive engineering and method for the production thereof
DE69829973D1 (en) Method with high throughput
DE69832512D1 (en) Fluorescent yellow and method for the production thereof
DE69738468D1 (en) Substituted pyrrolopyrimidines and method for the production thereof
DE69840853D1 (en) Pneumatic regulator and method
DE69832970D1 (en) Humanized antibodies and method for their manufacture
DE69830510D1 (en) Composite materials and method for the production thereof
DE69836729D1 (en) Anti-vefg antibodies
DE69931507D1 (en) Interferon-beta fusion proteins and its uses
DE60036294D1 (en) Covered transponder and method for the production thereof
DE69934967D1 (en) Method for reducing immunogenicity of proteins
DE69941696D1 (en) Micronadel devices and method for the production thereof
DE69839147D1 (en) Artificial antibody polypeptide
DE69927600D1 (en) Biotechnically constructed tissue and method for the production and use thereof
DK0896586T3 (en) ErbB3 antibodies
DK2261358T3 (en) New streptococcus antigen
DE69837524D1 (en) Method for producing an anchoring, anchoring part and tensioning element for this purpose
DE60027125D1 (en) Zip and arrangements and method for the production thereof
DE60027698D1 (en) Load-loading osteoimplantate and method for the production thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1053329

Country of ref document: EP